A Phase 3 Study to Evaluate the Potential Impact of Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
Latest Information Update: 22 Oct 2023
At a glance
- Drugs Neflamapimod (Primary)
- Indications Lewy body disease
- Focus Registrational; Therapeutic Use
- Sponsors CervoMed; EIP Pharma
- 09 Oct 2020 New trial record
- 06 Oct 2020 According to an EIP Pharma media release, based on the Phase 2 study (NCT04001517) results which demonstrate proof-of-concept of neflamapimod as a treatment for patients with DLB, the company plans to advance development of neflamapimod into Phase 3 study.